<DOC>
	<DOCNO>NCT01786603</DOCNO>
	<brief_summary>ALS disorder weaken motor strength lung function . Rapid loss motor neuron brain spinal cord ALS patient cause symptom increase weakness loss muscle function . Motor neuron responsible send signal muscle body trigger movement . While drug help relieve symptoms ALS , cure ALS . Rasagiline drug possible neuroprotective characteristic . Neuroprotective mean nervous system may protect weakening . It known rasagiline possible neuroprotective characteristic , effectiveness rasagiline patient ALS test . Rasagiline approve treatment Parkinson 's disease . Rasagiline treatment ALS approve U.S. Food Drug Administration ( FDA ) investigational . Investigational drug study find safe effective treatment disease condition . By study , researcher hope learn rasagiline safe slow disease progression patient ALS . Funding Source - FDA OOPD .</brief_summary>
	<brief_title>Rasagiline Subjects With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>The study phase II , double-blind , placebo-controlled , multicenter study rasagiline 2mg/day . Subjects assign either active agent placebo ( 3:1 ) twelve month . Subjects undergo outpatient evaluation screen , baseline , month 1 , 2 , 4 , 6 , 8 , 10 12 telephone assessment month 3 , 5 , 7 9 . There close-out phone call 30 day post month 12 .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>1 . A clinical diagnosis laboratorysupported probable , probable , definite ALS , accord modify El Escorial criterion , study investigator ( Appendix IV ) . 2 . 21 80 year age inclusive . 3 . VC great equal 75 % predict screening baseline . 4 . Onset weakness within 2 year prior enrollment . 5 . If patient take riluzole ALS , must stable dose least thirty day prior baseline visit . 6 . Women childbearing age must nonlactating surgically sterile use effective method birth control negative pregnancy test . 7 . Willing able give sign informed consent approve Institutional Review Board ( IRB ) . Exclusion criteria 1 . Requirement tracheotomy ventilation noninvasive ventilation &gt; 23 hour per day . 2 . Patients sympathomimetic agent . This include pseudoephedrine , phenylephrine , phenylpropanolamine , ephedrine . 3 . Patients analgesic serotoninergic property meperidine , tramadol , methadone propoxyphene , flexeril . 4 . Patients fluoxetine fluvoxamine . 5 . Patients take amitriptyline &gt; 50 mg/d , trazodone sertraline &gt; 100 mg/d , citalogram &gt; 20 mg/d paroxetine &gt; 30 mg/d . 6 . Diagnosis neurodegenerative disease ( Parkinson disease , Alzheimer disease , etc ) . 7 . Clinically significant history unstable medical illness ( unstable angina , advanced cancer , etc ) last 30 day . 8 . Has diaphragm pace device plan obtain diaphragm pace device course study . 9 . History renal disease . 10 . History liver disease . 11 . Current pregnancy lactation . 12 . Limited mental capacity patient provide write informed consent comply evaluation procedure . 13 . History recent alcohol drug abuse noncompliance treatment experimental protocol . 14 . Vital Capacity ( VC ) &lt; 75 % predict . 15 . Receipt investigational drug within past 30 day . 16 . Women potential become pregnant practice effective birth control . 17 . Poorly control hypertensive subject rest blood pressure SBP &gt; 160 mmHg and/or DBP &gt; 95 mmHg . 18 . Use BiPAP screening .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>